RecruitingPhase 1Phase 2NCT06414473

CBD for Knee Osteoarthritis

Sub-Lingual Administration of Cannabidiol for Knee Osteoarthritis


Sponsor

University of Florida

Enrollment

30 participants

Start Date

Jun 14, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Osteoarthritis is a disease that affects millions of Americans and is the leading cause of persistent pain and physical disability in the older adult population. Many physically active Americans have reported pain-relieving effects of cannabidiol (CBD) that can reduce or eliminate use of nonsteroidal anti-inflammatory drugs (NSAIDs) for activity-related pain with minimal to no side effects. Long-term use of over-the-counter medications, including NSAIDs, can pose a significant health risk, and therefore clinical research on the safety and efficacy of CBD is needed.


Eligibility

Min Age: 40 YearsMax Age: 75 Years

Inclusion Criteria2

  • established clinical diagnosis of knee osteoarthritis (KOA)
  • moderate to severe knee pain (≥4/10) with physical activity in one or both knees

Exclusion Criteria12

  • pregnant (urine pregnancy test) or lactating
  • current cannabis (THC and/or CBD) use (urine drug screen)
  • any prior or ongoing medical condition that, in the investigators' opinion, could adversely affect the safety of the subject
  • any major surgery within 3 months prior to recruitment or planned orthopedic surgery for any time during this study which would interfere with the ability to report pain or quality of life outcome measures
  • any exposure to another investigational drug within 3 months prior to screening
  • BMI ≥ 45
  • current use of any enzyme-modifying drugs, including strong inhibitors or strong inducers of cytochrome P (CYP) enzymes
  • history of:
  • suicidal ideation or self-harm behavior
  • seizure disorder or traumatic brain injury,
  • liver or kidney disease, and
  • cardiovascular diseases

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCannabidiol (CBD) Extract

Administered thrice daily (with food) using a sublingual route of administration

DRUGPlacebo

Administered thrice daily (with food) using a sublingual route of administration


Locations(1)

Sports Medicine Research Laboratory

Gainesville, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06414473


Related Trials